|
Siltuximab Clinical Trials
6 actively recruiting trials across 4 locations
▲ +1 trial since May 2026
Also known as: Anti-IL-6 Chimeric Monoclonal Antibody, CNTO 328, CNTO-328, Sylvant, cCLB8
Pipeline
Phase 1: 1Phase 2: 4Phase 2/3: 1
Top Sponsors
- Yuanquan Yang1
- Taylor Brooks1
- Merck Sharp & Dohme LLC1
- Memorial Sloan Kettering Cancer Center1
- Massachusetts General Hospital1
Indications
- Cancer6
- CRS - Cytokine Release Syndrome1
- Cytokine Release Syndrome1
- Schwannomas1
- Schwannomatosis1
Other2 trials
Boston, Massachusetts1 trial
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Massachusetts General Hospital Cancer Center
Phase 2
Basking Ridge, New Jersey1 trial
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2
Cleveland, Ohio1 trial
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Phase 1
Columbus, Ohio1 trial
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.